BioCity Biopharma
Wuxi, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
OncologyImmunology
Technology Platform
Modality-agnostic drug discovery and development, with capabilities spanning small molecules, monoclonal/bispecific antibodies, and antibody-drug conjugates (ADCs), supported by a translational medicine center.
Opportunities
Significant opportunity in the large, underserved nephrology market with lead asset SC0062, which has shown positive Phase 2 data in two major kidney diseases and holds Breakthrough Therapy Designation.
Global expansion of its first-in-class oncology ADC pipeline (BC3195, BC2027) through strategic combinations and partnerships presents another major growth vector.
Risk Factors
Clinical development risks across a broad pipeline, particularly for novel, first-in-class mechanisms like the CDH3 and GPC3 ADCs.
Intense competition in both the kidney disease (from companies like Travere, Chinook) and oncology ADC spaces, alongside dependence on future financing to advance multiple programs to late-stage trials.
Competitive Landscape
In nephrology, competes with other endothelin antagonists (e.g., sparsentan) and novel mechanisms; differentiation for SC0062 lies in its ETA-selectivity and strong mid-stage data. In oncology, faces intense competition in the ADC field but seeks differentiation through novel targets like CDH3 and GPC3.